In the acute phase of systemic lupus erythematosus the serum contains factors, with molecular weights ranging from 780,000 daltons to 1.5 million daltons, which induce blast transformation of autologous lymphocytes. In addition to the high-molecular weight components, low-molecular weight factors (75,000 and 160,000 daltons) which also induce an increase in lymphocytic transformation have also been demonstrated. In contrast to the high-molecular weight components the low-molecular factors stimulate the transformation of autologous and homologous lymphocytes. During transformation, lysis of autologous target fibroblasts occurs. The low-molecular weight mitogenic components remain stable after 30 min at 56 degrees C. The significance of such mediators for the pathogenesis of systemic lupus erythematosus is discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1523-1747.ep12543447 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lupus and inflammatory bowel disease share a common set of microbiome features distinct from other autoimmune disorders.
Ann Rheum Dis
January 2025
Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York, USA. Electronic address:
Objectives: This study aims to elucidate the microbial signatures associated with autoimmune diseases, particularly systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD), compared with colorectal cancer (CRC), to identify unique biomarkers and shared microbial mechanisms that could inform specific treatment protocols.
Methods: We analysed metagenomic datasets from patient cohorts with six autoimmune conditions-SLE, IBD, multiple sclerosis, myasthenia gravis, Graves' disease and ankylosing spondylitis-contrasting these with CRC metagenomes to delineate disease-specific microbial profiles. The study focused on identifying predictive biomarkers from species profiles and functional genes, integrating protein-protein interaction analyses to explore effector-like proteins and their targets in key signalling pathways.
Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs.
Ann Rheum Dis
January 2025
Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
The increasing prevalence of autoimmune and immune-mediated diseases (AIMDs) underscores the need to understand environmental factors that contribute to their pathogenesis, with the microbiome emerging as a key player. Despite significant advancements in understanding how the microbiome influences physiological and inflammatory responses, translating these findings into clinical practice remains challenging. This viewpoint reviews the progress and obstacles in microbiome research related to AIMDs, examining molecular techniques that enhance our understanding of microbial contributions to disease.
View Article and Find Full Text PDFBarriers and facilitators to sustaining a lupus patient decision aid in regular rheumatology outpatient care in the US.
Rheumatology (Oxford)
January 2025
Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Objective: This study investigates the barriers and facilitators to sustaining a decision aid (DA) tool for patients with systemic lupus erythematosus (SLE) in routine rheumatology outpatient care across the U.S. The DA was initially developed for assisting Patients with SLE in making informed medication choices by providing personalized information on their treatment process.
View Article and Find Full Text PDFThe emerging role of Bruton's tyrosine kinase inhibition in Urticaria Management.
Expert Opin Drug Saf
January 2025
Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Introduction: Bruton's tyrosine kinase (BTK) is a cytoplasmic signaling protein expressed across a variety of immune cells, terminally differentiated plasma cells, and natural killer cells. Due to the signal potential and targetable nature of BTK, the use of BTK inhibitors (BTKis) has been proposed for the management of several diseases. Currently, the use of BTKis is under investigations for several dermatological conditions such as pemphigus, systemic lupus erythematosus, hidradenitis suppurativa, atopic dermatitis, and chronic spontaneous urticaria (CSU).
View Article and Find Full Text PDFBig Heart, Small Shoes: Heart Failure in Systemic Lupus Erythematosus, More Than Lupus Cardiac Involvement.
CJC Open
January 2025
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!